36 annotations
new ICU bed
(No comment added)
Transcript
2022 Q4
10 Feb 23
As we went through the fourth quarter, we were still purchasing electronic components at much higher levels than we anticipated. The spot market was very challenging
(No comment added)
Transcript
2022 Q4
10 Feb 23
inflationary pressures to begin to ease in the second half of the year
(No comment added)
Transcript
2022 Q4
10 Feb 23
cost base is still elevated relative to historic norms
(No comment added)
Transcript
2022 Q4
10 Feb 23
strategic actions, including potential product line and country exits to better position the company for more profitable growth over the mid to long term These exits are expected to reduce sales by more than $100 million as compared to full year '22
(No comment added)
Transcript
2022 Q4
10 Feb 23
our expectation is that supply for electromechanical components will improve in the second half of the year
(No comment added)
Transcript
2022 Q4
10 Feb 23
We experienced record levels of backorders and backlog, particularly for the legacy Hillrom business.
(No comment added)
Transcript
2022 Q4
10 Feb 23
new planned product introductions include more than 5 injectable drug launches, a next-gen ICU bed, ExactaMix Pro, Nutrition Compounder, continued rollout of our Novum IQ LVP and syringe pump in Canada and launch of the Novum IQ syringe pump in the U.S.
(No comment added)
Transcript
2022 Q4
10 Feb 23
We are also actively pursuing strategic alternatives for our BioPharma Solutions business,
(No comment added)
Transcript
2022 Q4
10 Feb 23
freight and supply chain constraints
(No comment added)
Transcript
2022 Q4
10 Feb 23
Legacy Hillrom sales grew mid-single digits on a pro forma and FX-neutral basis as compared to Q4 2021. This growth reflects demand for the physical assessment and cardiology portfolios within the Front Line Care business.
(No comment added)
Transcript
2022 Q4
10 Feb 23
lower in-center HD sales due to HD monitor and associated consumable component supply challenges.
(No comment added)
Transcript
2022 Q4
10 Feb 23
adjusted earnings decreased 15% to $0.88 per share outside our guidance range of $0.92 to $0.99 per share.
(No comment added)
Transcript
2022 Q4
10 Feb 23
These supply constraints are a mixture of electromechanical components and shortages from other third-party suppliers.
(No comment added)
Transcript
2022 Q4
10 Feb 23
are expect to deliver more than $300 million in total savings during 2023 and a workforce reduction of less than 5%.
(No comment added)
Transcript
2022 Q4
10 Feb 23
manufacturing footprint in a more resilient supply chain
(No comment added)
Transcript
2022 Q4
10 Feb 23
spin Kidney Care into an independent publicly traded company in the next 12 to 18 months
(No comment added)
Transcript
2022 Q4
10 Feb 23
This new operating model is focused on 4 vertically integrated global business units, or GBUs, grouped along general therapeutic areas encompassing multiple sites of care.
(No comment added)
Transcript
2022 Q4
10 Feb 23
improve our commercial responsiveness, reinvigorate our innovation engine and streamline our operations
(No comment added)
Transcript
2022 Q4
10 Feb 23
this top line growth was offset by weighing of macroeconomic and supply chain factors that has continued to put pressure on the cost of doing business.
(No comment added)
Transcript
2022 Q4
10 Feb 23